The newly developed antibody 6H4 fragments (Fabs) specific to A? oligomers, encapsulated in the polymeric nanomicelles (PMs), were peripherally administrated to AD model mouse for 10 weeks. In mice that were administered anti-A?O 6H4 Fabs in the PMs, various toxic A? species (A? oligomers, A?42s, N3pE A?s, A?s with toxic conformer) and the presence of A? plaques with dense cores in the brain were significantly reduced. Additionally, suppression of the progression of pathological processes of AD was supported by the prevention of cognitive-behavioral decline in the spatial memory tests.
CREDIT: Department of Neurology and Neurological Science, TMDU
Researchers led by Tokyo Medical and Dental University (TMDU) find that antibody fragments encapsulated in nanomicelles cross the blood–brain barrier and reduce the levels of toxic A? species in the brain of an Alzheimer’s disease model mouse
Sometimes the best things in life come by chance, when we happen to be in the right place at the right time. Now, researchers from Japan have found a way to ensure that new medications are delivered to the right place in the body and at the right timepoint in disease progression, so that they have the best effect.
In a study published recently in the Journal of Nanobiotechnology, researchers led by Tokyo Medical and Dental University (TMDU) have revealed that a novel delivery system delivers treatment to where it is needed most in a mouse model of Alzheimer’s disease (AD).
AD is a common neurodegenerative disease that causes dementia. It is characterized by the accumulation of a protein called amyloid ? (A?) in the brain, and a number of different toxic forms of A? have been identified that impair brain function, notably A? oligomers (A?Os).
“Multiple clinical trials have attempted to use an anti-A? antibody to treat AD, but the results have been unsatisfactory,” says lead author of the study Akiko Amano. “One potential explanation for this is that the blood–brain barrier (BBB) prevents most full-length antibodies from entering the brain.”
To address this challenge, the researchers previously developed glucosylated (sugar-linked) polymeric nanomicelles (PMs), which are tiny, hollow balls that could successfully cross the BBB via transcytosis in mouse brain capillary endothelial cells; this process was mediated by glucose-transporter-1 and induced by an increase in blood glucose levels after the mice experienced fasting conditions. In this study, Takanori Yokota and colleagues filled PMs with fragments of an anti-A?O antibody, injected them into a mouse model of AD, and assessed the effects on the brain and on behavior.
“The results were very clear,” explains senior author Nobuo Sanjo. “Administration of anti-A?O antibody fragments through PMs significantly reduced the amounts of various toxic A? species. In addition, the A? plaques that did form were smaller and less dense than those seen in untreated mice.”
Next, the researchers analyzed the behavior of the mice and found that the mice treated with the antibody fragment-filled PMs had better learning and spatial memory than untreated mice. “Our findings suggest that delivering sufficient levels of antibodies to the brain using PMs can reduce toxic A? species and slow AD progression in mice,” says Amano.
Given that the failure of anti-A? antibodies to improve cognitive function in human clinical trials was likely because of an insufficient supply of the antibodies in the brain, PM-encapsulated antibody fragments could represent an effective way to prevent AD progression. In addition, new candidates for AD treatment that degrade toxic A?s and reduce their toxic effects could also be delivered to the brain using the same PM-based system.
Original Article: Transporting antibodies across the blood–brain barrier to treat Alzheimer’s disease
More from: Tokyo Medical and Dental University
The Latest Updates from Bing News
Go deeper with Bing News on:
Alzheimer’s disease
- Storing fat in certain area of the body may raise risk of Alzheimer’s disease - new study
Alzheimer’s disease is the most common type of dementia in the UK. A progressive condition, it affects memory and thinking skills over a number of years. Although it is not always known what causes ...
- My mother has dementia – these are the lifestyle changes I've made to avoid the same fate
I know: I know that when my mother is unkind or impossibly difficult it’s because her empathy and characteristic sweetness are being eaten away by Alzheimer’s. Understanding that the fundamental ...
- Anavex's Blarcamesine: Sigma-1 Receptor Agonists And Antioxidants For Alzheimer's Disease
Anavex's blarcamesine may be a more effective antioxidant than Aricept and galantamine in treating Alzheimer's. Click here to see why I rate AVXL stock a Buy.
- New Alzheimer’s blood test may determine who is at risk of dementia: 'Could be game changer'
A blood test may help identify individuals at risk for Alzheimer’s before they show any signs of disease, according to a new study published in the journal Nature Medicine.
- ‘That disease is terrible:’ Alzheimer’s Association hosts workshop connecting families with resources, more education
Not knowing who you are was a challenge. Getting her to eat was a challenge,” said Moaney. Those are Arlene Moaney words, describing life as a caregiver for her mother who battled with dementia before ...
Go deeper with Bing News on:
PM-encapsulated antibody fragments
- Understanding the evolution of antibody affinity maturation and humanization
Antibodies are essential for immune defense and safeguarding against bacteria, viruses, and other foreign entities. Produced by B cells, these protein molecules offer the potential for treating ...
- Method created to better remove protein causing Alzheimer’s
The researchers, primarily from Tokyo Medical and Dental University and the Innovation Center of Nanomedicine, encapsulated fragments of an antibody that can attach itself to the protein and ...
- Advances in Antibody Therapeutics
Elina is a PhD candidate at the University of Toronto studying the regulation of microbial shikimate dehydrogenase enzymes. Elina joined the Creative Services Team as an intern and assists with ...
- Antibody Fragments Market Size Expects To Cross US$ 13.41 Billion By 2032 With Monoclonal Antibodies Segment To Hold 95% Share X Herald
(MENAFN- Ameliorate Digital Consultancy) The antibody fragments market, currently valued at USD 7.56 billion, is predicted to develop at a compound annual growth rate (CAGR) of 5.9% during the ...
- Fc-Dependent Depletion of Activated T Cells Occurs Through CD40L-Specific Antibody Rather Than Costimulation Blockade
Low background activation of complement occurs in the absence of the CD40L-specific antibody (Fig. 3). In contrast, both C3c and C3d fragments were deposited on the surface of CD40L-expressing ...
